Dalmia Healthcare, the healthcare division of Dalmia Group
led by renowned industrialist Sanjay Dalmia, starts clinical trial to
evaluate the efficacy and safety of polyherbal combination "Astha-15"
for treatment of COVID-19. The Dalmia Centre for Research and
Development (DCRD), R&D entity of Dalmia Group after years of extensive
research, manufactured a polyherbal combination of 15 herbs called
Astha-15, also mentioned in the Indian System of Medicine.
Set regulatory guidelines of Informed Consent
Declaration, Insurance Terms and EC approvals will be followed to conduct the
Multi-centric, Phase III clinical trials. This phase III clinical trial has
been registered on CTRI with reg. no. CTRI/2020/06/025590.
The study comes in the back of the Ministry of
AYUSH last month recommending the use of herbal products like tea, spices, to
overcome the pandemic. The polyherbal combination "Astha-15",
made available by the Group on March 16, has previously undergone a randomized
double-blind, placebo-controlled study on patients, in speciality Govt. Hospital ,
Chennai , India
Now this polyherbal combination "Astha-15"
will undergo a phase III clinical trial with the most primary COVID-19 sites
across India
.JPG)
